Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
ROCKVILLE, Md., Aug. 31, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:
Citi 12th Annual Biotech Conference
Dates: Wednesday, September 6 – Thursday, September 7
Location: Mandarin Oriental, Boston
Panel: Gene Therapy Manufacturing and Regulatory Opportunities and Challenges; Thursday, September 7, 2017 at 11:00 a.m. ET
Morgan Stanley 15th Annual Global Healthcare Conference
Dates: Monday, September 11 – Wednesday, September 13
Location: Grand Hyatt, New York
Fireside chat: Wednesday, September 13, 2017 at 11:05 a.m. ET
Cantor Fitzgerald Global Healthcare Conference
Dates: Monday, September 25 – Wednesday, September 27
Location: InterContinental New York Barclay Hotel, New York
Company presentation: Tuesday, September 26, 2017 at 4:00 p.m. ET
A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
